Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1,645.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
1,643.00 1,644.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,887.87 402.27 134.81 10.9 3,809
Last Trade Time Trade Type Trade Size Trade Price Currency
19:14:08 O 113,344 1,634.087 GBX

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Investors    Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
29/6/202211:27Hikma Pharmaceuticals1,589
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,645.50p.
Hikma Pharmaceuticals Plc has a 4 week average price of 1,459.50p and a 12 week average price of 1,459.50p.
The 1 year high share price is 2,703p while the 1 year low share price is currently 1,459.50p.
There are currently 231,498,391 shares in issue and the average daily traded volume is 1,073,424 shares. The market capitalisation of Hikma Pharmaceuticals Plc is £3,809,306,023.91.
robertball: Not sure too. He was good at Teva and Hikma price rose after he joined.
dartboard1: Not really. PY generics revenue was 820, and forecast is 710-750. PY generics margin was 24 and forecast is 20. So agree generics is definitely not looking good this year, but there's two other divisions doing well, so group as a while is not in terminal decline as skeptical suggests. Zoom out and have a look at the growth over 5 years (not share price growth of course) and it's a good story
montyhedge: 2800p price target for Hikma by Barclays.
adamb1978: 10% share price fall seems very harsh for these revenues moving out perhaps 2-3 months!
robertball: The FT just said that share price subdues due to slow generics.
netcurtains: blue: That is the point, asuming there is nothing fundamentally wrong with HIK, it does appear to be quite cheap. HIK Pe 15 GSK Pe 19 AZN Pe (dont totally nuts). Of the three, if nothing wrong with HIK, then HIK is probably looking pretty good.
montyhedge: Right price for Hikma should be around 2600p on fundamentals but for some reason Hikma lowest rated pharma. Still buybacks picking up their own shares cheap. Will help of course eps and even lower p.e.
netcurtains: the normal TOTAL HIK share transactions on any given day are 1m (on good day) and 0.4m on average day and 02m on bad day. So, if they bought 5% every other day, they could keep it up for at least three months 5% more buys could actually make the share price rise quite a lot over a month or two or three or four I've edited this WINCANTON volume chart so you can see HIK volumes over the past year:
blue59: ‘ Any acquisitions under the Initial Tranche will be carried out within certain pre-set parameters, and in accordance with Hikma's general authority to repurchase Ordinary Shares as granted at Hikma's Annual General Meeting on 23 April 2021, pursuant to which the maximum number of Ordinary Shares to be bought back by Hikma may not exceed 24,333,210 Ordinary Shares.’ Am I reading that correctly? If the limit allowable to buy back is a total of 24m shares then the average price paid can’t be more that £9.27 per share????
cumnor: Starting to look good value-even the divi which should be increased, is not entirely token at this price. Given their expanding portfolio, esp in the US, should be trading at double this price compared to US peers. Bought this AM for the Sipp. Given the dire state of the UK market as a trading platform (look at the volumes in the likes of Hik, JDW etc) the share price could go anywhere in the short term but this is a solid, growing business.
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220630 06:48:02